Your basket is currently empty!
Kidney Cancer UK represents patients at NICE nivo+ipi appraisal
On 3rd February 2022, NICE approve the use of nivolumab with ipilimumab as a first line treatment for kidney ...
News Archive
NICE
NICE rejects pembro+axitinib therapy for aRCC
Kidney cancer community strongly disagrees with NICE decision not to approve pembrolizumab with axitinib ...
NICE: Shared decision making
Author: Susanna Smith; BSc (Hons) Nursing and MSc Public Health
Kidney Cancer UK Health Professional
I recently ...
How we work with N.I.C.E
How Kidney Cancer UK works with N.I.C.E to bring new drugs treatments to patients
Author; Lucy Willingale Bsc ...
NICE recommend nivolumab + ipilimumab combo through CDF
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has ...
Kidney Cancer UK represents patients at NICE appraisals
On the 10th May 2018 the National Institute for Care and Health Excellence (NICE) appraised two different drug ...
NICE recommends tivozanib as first-line treatment for advanced renal cell carcinoma
EUSA Pharma has announced that the National Institute for Health and Care Excellence (NICE) has published a Final ...
Hopes for Cabozantinib NICE recommendation
Kidney Cancer UK is very disappointed to hear that at the midpoint of the Single Technology Appraisal (STA) of ...
Cabozantinib unlikely to be recommended based on cost: NICE and Ipsen in talks
NICE and Ipsen are continuing to discuss whether cabozantinib (Cabometyx) is to be recommended for use on the NHS ...
NICE approves kidney cancer drug for NHS use
Patients with advanced kidney cancer will have routine NHS access to the drug everolimus following recommendations ...
NICE recommends nivolumab
NICE recommends nivolumab: Kidney Cancer UK is delighted that National Institute for Health and Care Excellence ...
New drug cabozantinib for treating advanced kidney cancer under NICE review.
New drug cabozantinib, for use in treating advanced kidney cancer (approved by the FDA in the USA), is currently ...
